ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

Endocrine Abstracts (2004) 7 P174

New approach in treatment of hyperandrogenism with triiodothyronine

G Kazanavicius

Institute and Clinic of Endocrinology Kaunas University of Medicine, Kaunas, Lithuania.

We examined hypothyroidism control criteria in women in previous study. Part of thyroxin was replaced by 12.5 micrograms triiodthyronine (T3). After T3 treatment constant increase of the level of sex hormone binding globulin (SHBG) was observed in all cases. The aim of the study to evaluate T3 influence on testosterone level in women, SHBG level and FAI. SHBG directly determines the level of free androgen index (FAI). We have included 18 women with the increased level of FAI in this study. All the women were prescribed 12.5 microgrames of triiodthyronine. The level of T, SHBG and FAI was examined before and after the one month duration of treatment. The level of SHBG has increased after the treatment from 42.58 plus/minus 4.25 nmol/l to 80.94plus/minus 9.05 nmol/l (p<0.0003). The level of testosterone has decreased from 3.02plus/minus 0.27 nmol/l to 1.95plus/minus 0.19 nmol/l (p<0.004). The level of FAI has decreased from 7.91plus /minus 0.85 to 2.85plus/minus 0.33 (p<0.000008). In conculsion: triiodthyronine is effectively increasing SHBG, decreasing testosterone level and FAI and can be approved in future studies as effective drug for treatment of hirsutism, hyperandrogenism and infertility.

Article tools

My recent searches

No recent searches.